Latest news with #CompanyoftheYear
Campaign ME
27-05-2025
- Business
- Campaign ME
Agency of The Year Middle East 2025 now open for entries
Entries are open for The Campaign Agency of The Year Middle East 2025 (AOTYME 2025) awards, which returns this December to recognise the region's top-performing agencies across creative, digital, media, PR, production and beyond. Back for the fourth edition of one of the region's most prestigious awards, AOTYME celebrates business performance, agency culture, innovation, and diversity. Submitting an entry to these awards allows you the chance to measure your agency's performance against the best in the business, boost client confidence, showcase your innovative strategies and strengths and inspire future growth through a recognition of your achievements. Unlike traditional awards within the industry that focus on creative work, these awards stand to highlight how you drive business outcomes through exceptional client-servicing, agency culture, DE&I, new business and more. Judges will consider factors such as business growth, client retention, expansion of integrated offerings, leadership and innovation, demonstrable investment in R&D, influence within the industry, and commitment to talent and culture as they evaluate entries. Entries can be made at a discounted rate for the early bird deadline of August 7, 2025. To download the full entry kit, click here. New categories available With six new categories among a total of 36, these awards are your chance to shine within the industry. This year, AOTYME 2025 also recognises in-house agencies, that function within a brand to service internal and external briefs. Holding Company of the Year This award recognises the top-performing holding company in the region based on its financial performance during the period from 1 July 2024 to 30 June 2025. In-House Agency of the Year This award recognises an internal agency entity within a brand, which services the brand and/or external clients of its own, and has demonstrated outstanding strategic impact, operational efficiency, and has driven business growth for the brand and its clients. Branding Agency of the Year This award recognises the best agencies specialising in helping organisations create, launch, define, reposition and manage their brand identity and direction. CSR Initiative of the Year This award recognises effective value-driven and community-oriented outreach by an agency that has had a tangible impact within specific societies and geographies. Winning companies will prove how they have gone beyond token gestures to have a positive impact on the planet and people's lives through their programmes. Head of Agency Now broken down by discipline, this category recognises the heads of Middle East agencies who have individually done the most to advance their agency in the industry across with separate awards for the sub-categories of Creative, Digital, Media/Performance, and PR. Head of Network This award recognises the heads of Middle East agencies who have individually done the most to advance their network in the industry. You can find out more about the Campaign Agency of The Year Middle East 2025 categories here.
National Business Review
23-05-2025
- Business
- National Business Review
Drone company Syos Aerospace named NZ Hi-Tech company of the year
Aerospace dominates the top gongs in this year's annual NZ Hi-Tech Awards with Mount Maunganui drone company Syos Aerospace winning Company of the Year and Rocket Lab founder Sir Peter Beck named Flying Kiwi. Syos founder Sam Vye told NBR in February that the four-year-old company hopes to triple
Yahoo
22-05-2025
- Business
- Yahoo
Former Zillow Executive Andrew Wild Joins Lofty to Spearhead Enterprise Sales
Industry veteran to help accelerate adoption of Lofty's award-winning AI powered platform among brokerages nationwide Andrew Wild, Vice President, Enterprise Sales, Lofty PHOENIX, May 22, 2025 (GLOBE NEWSWIRE) -- Award-winning real estate technology innovator, Lofty today announced 20+ year industry veteran Andrew Wild has joined the company as Vice President of Enterprise Sales. The former Zillow executive will lead Lofty's enterprise sales strategy and team, focused on acquiring and expanding partnerships with brokerages across the U.S. Passionate about helping enterprises modernize their tech operations, Andrew will help evangelize the power of Lofty's innovative platform to streamline operations, improve data visibility and drive agent productivity. To learn more about how Lofty's innovations can help your enterprise brokerage drive business growth, visit Lofty Wins Company of the Year in Real Estate in 2025 American Business Awards. Read more HERE. More than 70k agents and fast growing brokerages including Epique Realty, LPT and REAL rely on Lofty as their platform of choice. An industry veteran, Andrew understands however, that many brokerages are still stuck in a technology rut, beholden to legacy, siloed systems. In his new role, Andrew will leverage his keen understanding of the challenges enterprise brokerages face to help educate the market on the transformation power of Lofty and accelerate adoption of the AI-powered platform, designed to support the entire real estate process – from search to settlement. An original revenue team member at Zillow, Andrew spent the last two plus decades honing his skills in real estate and SaaS sales. Previously, Andrew led enterprise sales for Dotloop and Premier Broker and held a leadership position at Tom Ferry, fostering strategic partnerships with top brokerages and teams nationwide. 'I'm excited to join Lofty and help drive the next phase of growth in enterprise real estate tech,' said Andrew Wild, Vice President, Enterprise Sales, Lofty. 'I'm especially looking forward to helping Lofty build on its growing enterprise adoption and AI innovation, which is finally giving the company a seat at the table in major enterprise tech conversations. There's huge potential to give brokers and teams more control over lead-to-transaction workflows—outside of the portals—and to truly drive business results.' To learn more about how Lofty's unmatched AI capabilities can help your business grow, visit About Lofty Inc. (formerly Chime Technologies) provides an AI-powered platform that helps real estate professionals increase their productivity and accelerate business growth. Featuring award-winning technology, the Lofty platform is designed to optimize every step of the real estate journey, from search to settlement. By leveraging one unified hub, customers can automate marketing programs, streamline the sales process, and maximize collaboration between agents, empowering them to spend more time building relationships and their business. Headquartered in Phoenix, Arizona, Lofty provides proven solutions for brokers, teams, and the enterprise. For more information, visit Media Contact:Sarah Murray Attune Communicationssarah@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker
Novo Nordisk (NVO) CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an all-time high in the markets. Despite being the first-to-market in the latest generation of GLP-1 drugs, notably with its well-known diabetes drug Ozempic and weight loss drug Wegovy, Novo has recently faced several headwinds, causing the stock to suffer. That includes missing sales estimates in first quarter earnings this year. Those headwinds contributed to the decision Friday, the company said in a statement. "Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders," the statement said. Jørgensen, who has been with the company since 1991, will stay on through the transition as the company searches for a new leader. Novo's stock was trading down more than 5% in premarket trading Friday. In June 2024, the company was trading ata high of more than $140 per share, and the stock is up nearly 107% in the past five years. Novo had to upgrade its guidance three times that year. It was why Yahoo Finance named it the 2023 Company of the Year. In June 2024, the company was trading at a high of more than $140 per share, and the stock is up nearly 107% in the past five years. After years of being known for its insulin and diabetes products, Novo produced what some have deemed an accidental blockbuster in the form of Ozempic, a diabetes treatment that showed greater weight loss than any prior treatment. It subsequently released Wegovy to target obesity. The move has been credited with changing the narrative and stigma around obesity. But trouble for the company began brewing when its popularity outstripped its supply, and the company began to face stiff competition with Eli Lilly (LLY). Despite recent efforts, like partnering with telehealth firm Hims & Hers (HIMS), and sealing an exclusive deal for CVS's (CVS) drug formulary — Wall Street appears unimpressed. Lilly followed Novo with similar drugs, for both the diabetes and obesity categories, within a year. With greater weight loss potential, Lilly's drugs also soon became popular, and the race began. Both companies suffered shortages of their drugs, spurring a robust— and profitable — copycat market for compounding pharmacies. The FDA has since taken both companies' drugs off the shortage list, but the compounders appear to be determined to continue selling copycats where they can. Lilly was able to get its drugs off the shortage list sooner, and has been able to ramp up manufacturing. Novo's parent company bought an existing contract manufacturer, Catalent, and sold three sites to Novo to help ease the production constraints. Despite both mirroring efforts to compete, Lilly appears to be leading the race. Most recently, its weight loss drug Zepbound overtook Wegovy for new prescriptions. And Novo Nordisk missed first quarter sales this year,and cut its full year guidance. The result has been pressure on the stock, and questions from Wall Street about whether or not it can continue to compete in the GLP-1 space. "Not sure buy that that the entire delta is due to compounders, but stock washed out. Cleary need to regain share/confidence," Mizuho's healthcare expert Jared Holz said in a note to clients earlier this month. Jørgensen's announcement marks the second surprising large healthcare CEO departure this week, as the sector faces several headwinds and underperforms the broader markets. Jørgensen is expected to be elected to the company's board in 2026. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker
Novo Nordisk (NVO) CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an all-time high in the markets. Despite being the first-to-market in the latest generation of GLP-1 drugs, notably with its well-known diabetes drug Ozempic and weight loss drug Wegovy, Novo has recently faced several headwinds, causing the stock to suffer. That includes missing sales estimates in first quarter earnings this year. Those headwinds contributed to the decision Friday, the company said in a statement. "Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders," the statement said. Jørgensen, who has been with the company since 1991, will stay on through the transition as the company searches for a new leader. Novo's stock was trading down more than 5% in premarket trading Friday. In June 2024, the company was trading ata high of more than $140 per share, and the stock is up nearly 107% in the past five years. Novo had to upgrade its guidance three times that year. It was why Yahoo Finance named it the 2023 Company of the Year. In June 2024, the company was trading at a high of more than $140 per share, and the stock is up nearly 107% in the past five years. After years of being known for its insulin and diabetes products, Novo produced what some have deemed an accidental blockbuster in the form of Ozempic, a diabetes treatment that showed greater weight loss than any prior treatment. It subsequently released Wegovy to target obesity. The move has been credited with changing the narrative and stigma around obesity. But trouble for the company began brewing when its popularity outstripped its supply, and the company began to face stiff competition with Eli Lilly (LLY). Despite recent efforts, like partnering with telehealth firm Hims & Hers (HIMS), and sealing an exclusive deal for CVS's (CVS) drug formulary — Wall Street appears unimpressed. Lilly followed Novo with similar drugs, for both the diabetes and obesity categories, within a year. With greater weight loss potential, Lilly's drugs also soon became popular, and the race began. Both companies suffered shortages of their drugs, spurring a robust— and profitable — copycat market for compounding pharmacies. The FDA has since taken both companies' drugs off the shortage list, but the compounders appear to be determined to continue selling copycats where they can. Lilly was able to get its drugs off the shortage list sooner, and has been able to ramp up manufacturing. Novo's parent company bought an existing contract manufacturer, Catalent, and sold three sites to Novo to help ease the production constraints. Despite both mirroring efforts to compete, Lilly appears to be leading the race. Most recently, its weight loss drug Zepbound overtook Wegovy for new prescriptions. And Novo Nordisk missed first quarter sales this year,and cut its full year guidance. The result has been pressure on the stock, and questions from Wall Street about whether or not it can continue to compete in the GLP-1 space. "Not sure buy that that the entire delta is due to compounders, but stock washed out. Cleary need to regain share/confidence," Mizuho's healthcare expert Jared Holz said in a note to clients earlier this month. Jørgensen's announcement marks the second surprising large healthcare CEO departure this week, as the sector faces several headwinds and underperforms the broader markets. Jørgensen is expected to be elected to the company's board in 2026. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem.
